Payment overview · 2025
General Payments
$148,212.38
158 reported records · 36 companies
Healthcare provider profile · identity verified
Eric Scott Schaefer, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · ROGERS, AR · NPI 1558325118
Verified facts
What the public records show
CMS Open Payments records show Eric Scott Schaefer, M.D. received $148,212.38 in general payments during 2025 across 158 reported records.
Cornerstone Specialty Network LLC accounted for 68.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ojjaara, Tagrisso.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Venclexta by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 98 records involving 88 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Xtandi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Calquence by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAGRISSO as an associated drug or biological on 5285 records involving 2776 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Tagrisso by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Venclexta as an associated drug or biological on 2896 records involving 2018 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Venclexta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OJJAARA as an associated drug or biological on 12602 records involving 5639 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ojjaara by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jakafi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Xarelto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Xtandi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Cornerstone Specialty Network LLC | Unresolved — no canonical attribution shown | $101,309.00 | 68.3% | 31 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $18,312.38 | 12.4% | 21 | 2025 |
| OnMark, Inc. | Unresolved — no canonical attribution shown | $11,067.09 | 7.5% | 15 | 2025 |
| SANOFI US SERVICES INC. | Unresolved — no canonical attribution shown | $6,710.95 | 4.5% | 6 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $2,791.81 | 1.9% | 7 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $1,948.19 | 1.3% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $1,467.89 | 1.0% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $1,314.98 | 0.9% | 2 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $1,080.00 | 0.7% | 1 | 2025 |
| Janssen Global Services, LLC | Unresolved — no canonical attribution shown | $575.00 | 0.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $557.80 | 0.4% | 13 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $195.54 | 0.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $98.34 | 0.1% | 5 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $94.68 | 0.1% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $80.88 | 0.1% | 4 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $76.90 | 0.1% | 5 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $75.03 | 0.1% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $57.67 | 0.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $54.21 | 0.0% | 4 | 2025 |
| Blueprint Medicines Corporation | Unresolved — no canonical attribution shown | $51.32 | 0.0% | 2 | 2025 |
| US Oncology Corporate, Inc. | Unresolved — no canonical attribution shown | $31.05 | 0.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $28.83 | 0.0% | 2 | 2025 |
| Nuvation Bio Inc. | Unresolved — no canonical attribution shown | $27.63 | 0.0% | 1 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $23.33 | 0.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $19.49 | 0.0% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.52 | 0.0% | 1 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $15.99 | 0.0% | 1 | 2025 |
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.47 | 0.0% | 1 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $15.42 | 0.0% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $15.17 | 0.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.03 | 0.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.50 | 0.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.12 | 0.0% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $13.68 | 0.0% | 1 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $13.46 | 0.0% | 1 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $12.03 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $72,980.25 | 10 |
| Consulting Fee | $36,960.75 | 30 |
| Honoraria | $30,739.00 | 19 |
| Food and Beverage | $3,882.71 | 92 |
| Travel and Lodging | $3,649.67 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $7,676.64 | 10 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological, Drug | Blueprint Medicines Corporation, GENZYME CORPORATION, SANOFI US SERVICES INC. | $6,778.47 | 9 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $6,422.85 | 6 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $2,791.81 | 7 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc., Janssen Scientific Affairs, LLC | $1,748.56 | 8 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $1,262.50 | 1 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Global Services, LLC | $575.00 | 1 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $335.00 | 1 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $195.54 | 2 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $164.21 | 9 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $98.34 | 5 | 2025 |
Source payment records
|
|||||
| PEMRYDI RTU Normalized: pemrydi rtu |
Drug | Amneal Pharmaceuticals LLC | $94.68 | 1 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $58.83 | 2 | 2025 |
Source payment records
|
|||||
| Tecentriq Normalized: tecentriq |
Biological | Genentech USA, Inc. | $57.67 | 3 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $51.86 | 3 | 2025 |
Source payment records
|
|||||
| ZEPZELCA Normalized: zepzelca |
Drug | JAZZ PHARMACEUTICALS INC. | $48.87 | 3 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $41.03 | 2 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $40.89 | 3 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | PFIZER INC. | $40.89 | 3 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $29.47 | 2 | 2025 |
Source payment records
|
|||||
| ZIIHERA Normalized: ziihera |
Drug | JAZZ PHARMACEUTICALS INC. | $28.03 | 2 | 2025 |
Source payment records
|
|||||
| IBTROZI Normalized: ibtrozi |
Drug | Nuvation Bio Inc. | $27.63 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Drug | AstraZeneca Pharmaceuticals LP | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| Epkinly Normalized: epkinly |
Drug | Genmab U.S., Inc. | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| Doptelet Normalized: doptelet |
Drug | SOBI, INC | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | Sumitomo Pharma America, Inc. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $13.32 | 1 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $13.32 | 1 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $12.03 | 1 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $12.03 | 1 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $12.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| OJJAARA ojjaara |
2025 | Ojjaara | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TAGRISSO tagrisso |
2025 | Tagrisso | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 98 supporting records · 88 recipient NPIs · example record 1228800820 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TAGRISSO open payments reported associated product |
CMS Open Payments — General Payments 5285 supporting records · 2776 recipient NPIs · example record 1206131546 |
Tagrisso · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Venclexta open payments reported associated product |
CMS Open Payments — General Payments 2896 supporting records · 2018 recipient NPIs · example record 1211488584 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | OJJAARA open payments reported associated product |
CMS Open Payments — General Payments 12602 supporting records · 5639 recipient NPIs · example record 1190332357 |
Ojjaara · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
106 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
58 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ondansetron Odt | Ondansetron | 143 | 95 |
| Potassium Chloride | Potassium Chloride | 124 | 56 |
| Prednisone | Prednisone | 118 | 69 |
| Levofloxacin | Levofloxacin | 113 | 86 |
| Xarelto | Rivaroxaban | 106 | 24 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 103 | 82 |
| Letrozole | Letrozole | 93 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 78 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 78 | 24 |
| Olanzapine | Olanzapine | 73 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 67 | 27 |
| Jakafi | Ruxolitinib Phosphate | 65 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 63 | 41 |
| Furosemide | Furosemide | 60 | 29 |
| Gabapentin | Gabapentin | 60 | 28 |
| Eliquis | Apixaban | 58 | 19 |
| Hydroxyurea | Hydroxyurea | 47 | 12 |
| Hydrocortisone | Hydrocortisone | 46 | 16 |
| Omeprazole | Omeprazole | 46 | 16 |
| Tramadol Hcl | Tramadol Hcl | 45 | 19 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Celecoxib | Celecoxib | 36 | 18 |
| Trazodone Hcl | Trazodone Hcl | 34 | suppressed |
| Xtandi | Enzalutamide | 31 | suppressed |
| Acyclovir | Acyclovir | 29 | suppressed |
| Revlimid | Lenalidomide | 28 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 27 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | 13 |
| Tagrisso | Osimertinib Mesylate | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 24 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | suppressed |
| Allopurinol | Allopurinol | 23 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 22 | suppressed |
| Lisinopril | Lisinopril | 22 | 12 |
| Lorazepam | Lorazepam | 22 | 12 |
| Dexamethasone | Dexamethasone | 21 | 16 |
| Fluconazole | Fluconazole | 21 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 21 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 20 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Ojjaara | Momelotinib Dihydrochloride | 20 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Losartan Potassium | Losartan Potassium | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Calquence | Acalabrutinib Maleate | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Venclexta | Venetoclax | 14 | suppressed |
| Brukinsa | Zanubrutinib | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $148,212.38 · 158 records | Cornerstone Specialty Network LLC | ADCETRIS, AYVAKIT, BRAFTOVI, CABOMETYX, CARVYKTI, DATROWAY, Doptelet, ELAHERE, ELREXFIO, ENHERTU, ERLEADA, Epkinly, FRUZAQLA, GEMTESA, IBRANCE, IBTROZI, IMFINZI, JAYPIRCA, KEYTRUDA, KISQALI, LIBTAYO, LORBRENA, LYNPARZA, Lenvima, MEKTOVI, MI CANCER SEEK, MONJUVI, MONOFERRIC, OJJAARA, ORGOVYX, Onivyde, PEMRYDI RTU, PLUVICTO, RYBREVANT, SARCLISA, TAGRISSO, TECVAYLI, TUKYSA, Tecentriq, VERZENIO, WELIREG, ZEPZELCA, ZIIHERA | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ojjaara play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error